(2R,3R,4R,5R)-2-(hydroxymethyl)-5-(5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl)tetrahydrofuran-3,4-diyl diacetate | 847453-47-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3R,4R,5R)-2-(hydroxymethyl)-5-(5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl)tetrahydrofuran-3,4-diyl diacetate
• 英文别名: ANA975；5-amino-3-(2',3'-di-O-acetyl-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one；5-amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one base；5-amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one；Isotorabine；[(2R,3R,4R,5R)-4-acetyloxy-5-(5-amino-2-oxo-[1,3]thiazolo[4,5-d]pyrimidin-3-yl)-2-(hydroxymethyl)oxolan-3-yl] acetate
• CAS: 847453-47-8
• 化学式: C₁₄H₁₆N₄O₇S
• 分子量: 384.37
• InChiKey: ZWELIJXAKMASLK-UGKPPGOTSA-N

物化性质

• 沸点：
  649.2±65.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  180
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  (2R,3R,4R,5R)-2-(hydroxymethyl)-5-(5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl)tetrahydrofuran-3,4-diyl diacetate 在 盐酸 作用下， 以 乙醇 为溶剂， 以95.37%的产率得到5-amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one hydrochloride
  参考文献：
  名称：

  New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one

  摘要：

  该发明涉及5-氨基-3-(2',3'-二-O-乙酰-β-D-核糖呋喃糖苷)-3H-噻唑并[4,5-d]嘧啶-2-酮的新结晶盐，以及它们的生产和用途，含有这些盐和结晶形式的药物制剂。

  公开号：

  EP2019113A1
• 作为产物：
  描述：

  5-amino-3-(2',3'-di-O-acetyl-5'-O-tert-butyl-dimethylsilanyl-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one 在 吡啶 、 氢氟酸 作用下， 以 四氢呋喃 为溶剂， 以100%的产率得到(2R,3R,4R,5R)-2-(hydroxymethyl)-5-(5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl)tetrahydrofuran-3,4-diyl diacetate
  参考文献：
  名称：

  ANA975的发现：TLR-7激动剂isatoribine的口服前药。

  摘要：

  ANA975是一种5-氨基-3-β-D-呋喃呋喃糖基-3H-噻唑并[4,5-d]嘧啶-2-一衍生物，其合成是寻找一种小分子收费类似的伊沙托立宾的口服前药受体7（TLR-7）激动剂。研究了几种策略以实现ANA975的公斤级合成。描述了三个一般的总合成。在针对丙型肝炎病毒（HCV）的ANA975的I期临床研究中，血浆中快速转化为isatoribine的效果是提供与临床相关的isatoribine水平。

  DOI：

  10.1080/15257770701490472

文献信息

• Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
  申请人：Averett R. Devron

  公开号：US20050054590A1

  公开（公告）日：2005-03-10

  This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.

  这项发明涉及使用Toll样受体（TLR）7配体及其前药治疗或预防哺乳动物体内的丙型肝炎病毒感染的方法。更具体地，这项发明涉及口服给予一种或多种TLR7配体前药的治疗有效量，用于治疗或预防丙型肝炎病毒感染。将这些TLR7免疫调节配体及其前药口服给哺乳动物可提供治疗有效量并减少不良副作用。
• 3-B-D-ribofuranosylthiazolo [4,5-d] pyridimine nucleosides and uses thereof
  申请人：Averett R. Devron

  公开号：US20050070556A1

  公开（公告）日：2005-03-31

  The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.

  这项发明涉及3-β-D-核糖呋喃基噻唑并[4,5-d]吡啶嘧啶核苷及含有这种化合物的具有免疫调节活性的药物组合物。该发明还涉及这种化合物和组合物的治疗或预防用途，以及通过给予这种化合物的有效量来治疗本文描述的疾病和紊乱的方法。
• CARBONATE AND CARBAMATE PRODRUGS OF THIAZOLO[4,5-d]PYRIMIDINES
  申请人：Haley J. Gregory

  公开号：US20080020989A1

  公开（公告）日：2008-01-24

  The invention is directed to carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidine compounds, whose metabolized parent compound has immunomodulatory activity. The invention also relates to the therapeutic use of such prodrugs and pharmaceutical compositions thereof in treating disease states associated with abnormal cell growth, such as cancer.

  该发明涉及噻唑并[4,5-d]嘧啶化合物的碳酸酯和氨甲酸酯前药，其代谢的母化合物具有免疫调节活性。该发明还涉及利用这种前药及其药物组合物在治疗与异常细胞生长相关的疾病状态，如癌症。
• [EN] 3-beta-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF<br/>[FR] NUCLEOSIDES 3-20051222WO03045968A1ANADYS PHARMACEUTICALS INC [US]20030605WX1-20XUS5041426AROBINS ROLAND K [US], et al19910820compounds 6,7,41,42X1,2,12XWO03045968A1ANADYS PHARMACEUTICALS INC [US]20030605"Remington's Pharmaceutical Sciences"Remington's Pharmaceutical SciencesBARANOV ET AL., CHEM. HET. COMPOUNDS, vol. 11, 1975, pages 73BARANOV ET AL.CHEM. HET. COMPOUNDS19751173
  申请人：ANADYS PHARMACEUTICALS INC

  公开号：WO2005121162A1

  公开（公告）日：2005-12-22

  The invention is directed to 3-ß-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.

  本发明涉及3-ß-D-核糖呋喃噻唑[4,5-d]吡啶嘧啶核苷和含有此类化合物的药物组合物，具有免疫调节活性。本发明还涉及这类化合物和组合物的治疗或预防用途，以及通过给予这类化合物的有效剂量来治疗本文所述的疾病和疾病的方法。
• 3-Beta-D-Ribofuranosylthiazolo&lsqb; 4,5-D&rsqb; Pyridimine Nucleosides and Uses Thereof
  申请人：Averett Devron R.

  公开号：US20080070852A1

  公开（公告）日：2008-03-20

  The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.

  本发明涉及3-β-D-核糖呋喃基噻唑[4,5-d]嘧啶核苷及含有这种化合物的药物组合物，其具有免疫调节活性。本发明还涉及使用这种化合物和组合物进行治疗或预防，以及通过给予有效剂量的这种化合物来治疗本文所述的疾病和障碍的方法。